Virogin Biotech, a Vancouver, Canada-based developer of next-generation oncolytic virus (OV) therapeutics, has raised over $120 million in a Series D2 round of financing as the company looks to build its global R&D centre in China’s Shanghai city.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
